Levofloxacin Concomitant Versus Levofloxacin Sequential

ConditionHelicobacter Pylori Infection

Trial statusNot yet recruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18-80

SponsorDamascus Hospital

About this trial

The goal of this trial is to determine the efficacy of levofloxacin based sequential treatment regimen or concomitant levofloxacin based regimens as empirical first-line therapy in the Syrian population

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Positive rapid urease test (CLOtest).

Histologic evidence of H. pylori by modified Giemsa staining.

Positive 13C-urea breath test. without prior eradication therapy and are willing to receive therapy.

Disqualifiers

Children and teenagers aged less than 18 years.

Previous eradication treatment for H. pylori.

Patients who took any drug, which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.

History of gastrectomy.

Trial design

Design model

Parallel

Treatments tested in this trial

sequential
Drug
amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
Levofloxacin 500Mg Oral Tablet
Drug
Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid

Treatment groups

150 Participants

are divided into 2 treatment groups

Group A: sequentialExperimental treatment 1 intervention

Group B: concomitantActive comparator 1 intervention

Trial outcomes

Primary outcomes

Eradication rate of Helicobacter pylori infection

Eradication rate of Helicobacter infected patients

Time frame

8 week from begning of treatment

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Damascus Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: